404 N/A53.0 47.0 37.9 34.1 28.0 24.four 34.0 33.8 7.9 21.8 49.3 28.0.0.0.0.N/AN/A 22.six 77.Abbreviations: CARET, Carotene and Retinol Efficacy Trial; N/A, nonapplicable; PSA, prostate-specific antigen; SD, common deviation. The t-test for age at baseline and 2 tests for the categorical variables were utilized. b The numbers are numbers of participants and column percentages unless otherwise noted. c Under no circumstances smokers contributed an extremely tiny percentage (2 ). They had been recruited in the CARET as a result of their occupational asbestos exposure. d Body mass index: weight (kg)/height (m)2. e 1994 approximates the advent from the PSA era.Am J Epidemiol. 2013;177(10):1106?1110 Cheng et al.Table two. Distributions of Serum Fatty Acid Composition as Total Phospholipids ( )a Shown as the 25th, 50th (Median), and 75th Percentiles in the Carotene and Retinol Efficacy Trial, 1985?Nonaggressive Prostate Cancer Instances, b 25th Percentile Median 75th Percentile Aggressive Prostate Cancer Circumstances, c 25th Percentile Median 75th Percentile 25th Percentile Controls, d Median 75th PercentileFatty Acidsn-3 PUFAs 18:3n-3 (-linolenic) 20:3n-3 (eicosatrienoic) 20:5n-3 (eicosapentaenoic) 22:5n-3 (docosapentaenoic) 22:6n-3 (docosahexaenoic) Total n-3 n-6 PUFAs 18:2n-6 (linoleic) 18:3n-6 (-linolenic) 20:2n-6 (eicosadienoic) 20:3n-6 (dihomo–linolenic) 20:4n-6 (arachidonic) 22:2n-6 (docosadienoic) 22:4n-6 (docosatetraenoic) Total n-6 TFA 16:1 TFA 18:1 TFA 18:two 18.76 0.05 0.30 two.51 9.44 0.02 0.39 34.11 0.17 1.20 0.18 20.55 0.07 0.33 2.84 10.77 0.03 0.45 35.ten 0.20 1.63 0.23 22.29 0.09 0.37 3.22 12.17 0.04 0.51 36.58 0.24 2.07 0.28 18.95 0.05 0.31 2.52 9.31 0.03 0.39 33.82 0.16 1.18 0.18 20.75 0.07 0.34 2.95 10.47 0.03 0.44 35.33 0.20 1.59 0.23 22.44 0.09 0.38 three.45 11.52 0.04 0.50 36.39 0.24 2.12 0.28 18.83 0.05 0.31 2.54 9.52 0.02 0.39 34.07 0.17 1.20 0.18 20.57 0.07 0.34 2.94 ten.64 0.03 0.46 35.26 0.20 1.59 0.22 22.32 0.09 0.38 three.40 11.82 0.04 0.52 36.41 0.24 two.11 0.28 0.09 0.01 0.45 0.71 two.11 three.BuyDBCO-NHS ester 52 0.6,6′-Dibromo-2,2′-bipyridyl uses ten 0.02 0.58 0.80 two.59 4.08 0.11 0.02 0.75 0.90 three.14 four.72 0.09 0.01 0.44 0.71 2.12 three.53 0.10 0.02 0.59 0.81 2.52 4.08 0.11 0.02 0.76 0.91 three.14 4.81 0.09 0.01 0.42 0.71 2.09 three.53 0.10 0.02 0.56 0.81 two.56 4.05 0.12 0.02 0.75 0.91 3.16 4.Abbreviations: PUFA, polyunsaturated fatty acid; TFA, trans-fatty acid. a The summation of fatty acid shown within this table will not be one hundred due to the fact other groups (saturated and monounsaturated) of fatty acids usually are not listed. b There had been 368 circumstances with nonaggressive prostate cancer defined as stage 0 I tumors and Gleason score 7.PMID:27108903 c There were 273 instances with aggressive prostate cancer defined as stage III/IV tumors or Gleason score 7. d There had been 1,398 controls.acids have been composed of n-3 and n-6 PUFAs, respectively. The biggest elements were linoleic acid (20.57 ) followed by arachidonic acid (ten.64 ) amongst the n-6 PUFAs and DHA (two.56 ) among the n-3 PUFAs. Inside the main effect evaluation, no considerable association was observed for n-3 PUFAs (Tables 3 and 4) or for trans-fatty acids (Net Table 1 offered at http://aje.oxfordjournals.org/), but two n-6 PUFAs were inversely connected with prostate cancer danger. Men with dihomo–linolenic acid percentages in the fourth quartile have been at 34 decrease threat for nonaggressive prostate cancer, compared with these with all the percentages inside the initially quartile (odds ratio (OR) = 0.66, 95 confidence interval (CI): 0.47, 0.95; Ptrend = 0.024) (Table three). Docosatetraenoic acid was inversely associatedwith aggressive prostate cancer ri.